Developer docs
API playgroundTry for free, no card

Search company profiles

Sante Ventures

Full company profile

uuid00002u3

Namestring
Sante Ventures
Legal namestring
Santé Ventures
Websiteurl
sante.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Santé Ventures is a healthcare and life sciences venture capital firm founded in 2006 and headquartered in Austin, Texas, with a second regional office in Boston. The firm invests in early-stage companies across three core verticals — Biotech, Medtech, and Healthtech — and has built a portfolio of more than 60 companies through five consecutive venture funds, with total assets under management exceeding $1 billion. Notable portfolio exits include LDR Medical (Zimmer Biomet), Explorys (IBM), AbVitro (Bristol Myers Squibb), Millipede Medical and Claret Medical and Farapulse (all Boston Scientific), TVA Medical (BD), and Laminar (Johnson & Johnson); the broader firm has been associated with over $70 billion in aggregate disclosed portfolio M&A value.

The firm's product surface extends beyond private venture investing. Santé Capital operates a systematic liquid hedge fund strategy powered by MindRank™, a proprietary big-data, machine-learning, and natural-language-processing platform built to identify mispriced publicly traded securities. Santé Accel is an internal startup studio that incubates and forms seed-stage medtech, biotech, and healthtech companies, with the explicit purpose of feeding later-stage investment into the main Santé Ventures funds. The firm has also added an in-house AI Engineer role in 2026 to integrate machine learning and explainable AI into investment decision-making across both venture and public-equity strategies.

Santé generates revenue primarily through management fees on committed capital across its five venture funds, supplemented by carried interest from successful exits. The hedge fund arm generates management and performance fees from institutional LPs, family offices, and accredited investors. Deal flow is sourced through direct relationships with founders and through deep institutional partnerships with Stanford Biodesign, Mayo Clinic, Cleveland Clinic Innovations, and Mass General Brigham, while exits are facilitated by longstanding relationships with strategic acquirers across the healthcare universe. Fund V closed at $330 million in February 2026 — the firm's largest fund to date — and the limited partner base is described as expanded and diversified across domestic and international markets.

Short descriptiontext

Santé Ventures is an Austin-based healthcare and life sciences venture capital firm founded in 2006, managing over $1B across five funds and 60+ portfolio companies in Biotech, Medtech, and Healthtech, complemented by a systematic hedge fund (Santé Capital) and an internal startup studio (Santé Accel).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, life sciences investing, medical device investment, biotech early-stage funding, systematic hedge fund
Industry2 codes
PRIMARYFSANAAAK
Secondary Venture Funds (VC Secondaries)
SECONDARYFSANAAAL
Venture Debt Providers
NAICS code2 codes
  • Other Financial Vehicles525990
  • Other Investment Pools and Funds5259
Product category
Healthcare Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Capital Fund Management
TypeManaged Services
Description

Generates revenue through management fees and carried interest from limited partners across five venture capital funds focused on early-stage healthcare and life sciences investments; Fund V closed at $330M in February 2026 exceeding $300M target, with total AUM over $1B.

sante.com
2Santé Capital Systematic Hedge Fund
TypeManaged Services
Description

Systematic liquid hedge fund investment strategy utilizing MindRank™ proprietary software; generates risk-adjusted returns from mispriced publicly traded securities through quantitative models combining big data, machine learning, and natural language processing.

sante.com
Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Santé Capital
Description

Publicly traded securities investment arm using the proprietary MindRank™ systematic quantitative strategy built on big data, machine learning, and natural language processing

sante.com
+1 more record
Core offering1 text field

Santé Ventures is a healthcare and life sciences venture capital firm that invests in early-stage private companies across Biotech, Medtech, and Healthtech verticals, managing over $1 billion in capital across five venture funds and 60+ portfolio companies. Through its subsidiary Santé Capital, the firm also operates a systematic liquid hedge fund strategy using its proprietary MindRank™ AI/ML/NLP software to capture mispricing in publicly traded securities, and runs Santé Accel, a startup studio that incubates seed-stage opportunities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • $70 billion+ in combined acquisition value for three portfolio companies Louis Bock guided (SeaGen/Pfizer $43B, Horizon Therapeutics/Amgen $27B, Zogenix/UCB $2B)
+4 more records
Product overview1 text field

Santé Ventures operates a multi-strategy investment partnership combining two primary service lines: a private venture capital arm (Santé Ventures) that invests in early-stage Biotech, Medtech, and Healthtech companies, and a public securities arm (Santé Capital) that runs a systematic quantitative strategy powered by the proprietary MindRank™ software platform. The architecture pairs external capital deployment with an internal technology backbone: MindRank™ — built on big data, machine learning, and natural language processing — drives Santé Capital's liquid hedge fund strategy, while the venture side of the firm is supported by Santé Accel, a startup studio that incubates seed-stage medtech, biotech, and healthtech companies in preparation for follow-on investment from the main Santé Ventures funds. Together, these offerings reflect a unified platform where proprietary AI-driven investment technology and human-led company creation reinforce the firm's broader thesis of identifying innovative healthcare companies addressing unmet medical needs.

Product and service4 records
1Santé Ventures (Private Venture Capital)
CategoryPrivate Venture Capital / Healthcare Investing
Description

Private investment vehicle deploying capital into innovative early-stage healthcare companies with a focus in Biotech, Medtech, and Healthtech. Manages over $1 billion in capital across five venture funds and 60+ portfolio companies. Targeted at founders and institutional limited partners.

2Santé Capital (Systematic Liquid Hedge Fund)
CategorySystematic Hedge Fund / Public Securities
Description

Public securities strategy utilizing a systematic quantitative investment approach built on the proprietary MindRank™ software to generate risk-adjusted returns in mispriced publicly traded securities. Distributed to institutional LPs, family offices, and accredited investors via the firm's in-house capital formation team.

3Santé Accel (Startup Studio)
CategoryStartup Studio / Company Incubation
Description

Santé start-up studio focused on creating and fostering seed-stage medtech, biotech, and healthtech opportunities through incubation, company formation, talent matching, and coaching, preparing companies for follow-on investment from Santé's main funds.

4Santé Ventures Fund V
CategoryVenture Capital Fund
Description

Fifth and largest venture fund of Santé Ventures, closed with $330 million in committed capital, focused on early-stage investments in biotechnology, medical technology, and digitally enabled healthcare companies addressing unmet medical needs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-dedicated growth and venture firm investing in biotech, medtech, and healthtech; similar fund size, sector focus, and growth-stage orientation to Santé Ventures Funds III–V.

TypeDirect peer
Description

Healthcare-focused crossover fund that invests across public and private biotech and medtech; comparable to Santé's dual private venture + public systematic strategy and similar size/AUM profile.

TypeDirect peer
Description

Healthcare-focused venture firm investing across biotech, medtech, and healthtech with offices in the US, Canada, and Europe; comparable fund size, sector mix, and company-creation approach to Santé.

TypeDirect peer
Description

Early-stage biotech-focused venture firm that builds companies from inception in a model analogous to Santé Accel; comparable seed/Series A orientation, though with heavier biotech weighting and smaller fund sizes.

TypeDirect peer
Description

Dedicated life sciences platform within Bain Capital investing across biotech, medtech, and pharma services; co-investor with Santé (e.g., Apreo Health) and a directly comparable scaled healthcare specialist.

TypeDirect peer
Description

Healthcare-dedicated investment firm managing roughly $17B across private equity, growth equity, and public equity strategies spanning biotech, medtech, and diagnostics — directly comparable to Santé's combined Santé Ventures + Santé Capital platform.

TypeBroad incumbent
Description

Large, established healthcare and technology venture firm with multiple billion-dollar funds and broad biotech/medtech exposure; comparable thesis area but materially larger and more biotech-skewed than Santé.

TypeDirect peer
Description

Dedicated healthcare venture and growth firm investing across biotech, medtech, and pharma services with multiple sequential funds — closest peer in fund size, sector mix, and growth-stage focus.

TypeBroad incumbent
Description

Multi-stage venture firm with a dedicated healthcare practice investing across biotech, medtech, and healthtech; broader sector mandate than Santé but directly competitive for the same Series A/B healthcare rounds.

TypeDirect peer
Description

Early-stage life sciences venture firm investing in biotech and medtech with multiple sequential funds; closely comparable in fund size, sector focus, and operational value-add model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles28 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment118 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sante Ventures

Healthcare Venture Capitalsante.com

Santé Ventures is an Austin-based healthcare and life sciences venture capital firm founded in 2006, managing over $1B across five funds and 60+ portfolio companies in Biotech, Medtech, and Healthtech, complemented by a systematic hedge fund (Santé Capital) and an internal startup studio (Santé Accel).

What Sante Ventures does

Santé Ventures is a healthcare and life sciences venture capital firm founded in 2006 and headquartered in Austin, Texas, with a second regional office in Boston. The firm invests in early-stage companies across three core verticals — Biotech, Medtech, and Healthtech — and has built a portfolio of more than 60 companies through five consecutive venture funds, with total assets under management exceeding $1 billion. Notable portfolio exits include LDR Medical (Zimmer Biomet), Explorys (IBM), AbVitro (Bristol Myers Squibb), Millipede Medical and Claret Medical and Farapulse (all Boston Scientific), TVA Medical (BD), and Laminar (Johnson & Johnson); the broader firm has been associated with over $70 billion in aggregate disclosed portfolio M&A value.

The firm's product surface extends beyond private venture investing. Santé Capital operates a systematic liquid hedge fund strategy powered by MindRank™, a proprietary big-data, machine-learning, and natural-language-processing platform built to identify mispriced publicly traded securities. Santé Accel is an internal startup studio that incubates and forms seed-stage medtech, biotech, and healthtech companies, with the explicit purpose of feeding later-stage investment into the main Santé Ventures funds. The firm has also added an in-house AI Engineer role in 2026 to integrate machine learning and explainable AI into investment decision-making across both venture and public-equity strategies.

Santé generates revenue primarily through management fees on committed capital across its five venture funds, supplemented by carried interest from successful exits. The hedge fund arm generates management and performance fees from institutional LPs, family offices, and accredited investors. Deal flow is sourced through direct relationships with founders and through deep institutional partnerships with Stanford Biodesign, Mayo Clinic, Cleveland Clinic Innovations, and Mass General Brigham, while exits are facilitated by longstanding relationships with strategic acquirers across the healthcare universe. Fund V closed at $330 million in February 2026 — the firm's largest fund to date — and the limited partner base is described as expanded and diversified across domestic and international markets.

Sante Ventures firmographics

Firmographics
Name
Sante Ventures
Legal name
Santé Ventures
Website
https://sante.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Santé Ventures is an Austin-based healthcare and life sciences venture capital firm founded in 2006, managing over $1B across five funds and 60+ portfolio companies in Biotech, Medtech, and Healthtech, complemented by a systematic hedge fund (Santé Capital) and an internal startup studio (Santé Accel).
Ownership category
akta.pro rank

Sante Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Other Financial Vehicles (525990), Other Investment Pools and Funds (5259)
akta.pro industry
PRIMARYFSANAAAK
Secondary Venture Funds (VC Secondaries)
SECONDARYFSANAAAL
Venture Debt Providers

Keywords

  • Healthcare venture capital
  • Life sciences investing
  • Medical device investment
  • Biotech early-stage funding
  • Systematic hedge fund

Where Sante Ventures is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sante Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Fund Management: Generates revenue through management fees and carried interest from limited partners across five venture capital funds focused on early-stage healthcare and life sciences investments; Fund V closed at $330M in February 2026 exceeding $300M target, with total AUM over $1B.
  2. Santé Capital Systematic Hedge Fund: Systematic liquid hedge fund investment strategy utilizing MindRank™ proprietary software; generates risk-adjusted returns from mispriced publicly traded securities through quantitative models combining big data, machine learning, and natural language processing.

Go-to-market motion1 record

Distribution channels3 records

Sante Ventures product offering

Product offering

Core offering

Santé Ventures is a healthcare and life sciences venture capital firm that invests in early-stage private companies across Biotech, Medtech, and Healthtech verticals, managing over $1 billion in capital across five venture funds and 60+ portfolio companies. Through its subsidiary Santé Capital, the firm also operates a systematic liquid hedge fund strategy using its proprietary MindRank™ AI/ML/NLP software to capture mispricing in publicly traded securities, and runs Santé Accel, a startup studio that incubates seed-stage opportunities.

Product overview

Santé Ventures operates a multi-strategy investment partnership combining two primary service lines: a private venture capital arm (Santé Ventures) that invests in early-stage Biotech, Medtech, and Healthtech companies, and a public securities arm (Santé Capital) that runs a systematic quantitative strategy powered by the proprietary MindRank™ software platform. The architecture pairs external capital deployment with an internal technology backbone: MindRank™ — built on big data, machine learning, and natural language processing — drives Santé Capital's liquid hedge fund strategy, while the venture side of the firm is supported by Santé Accel, a startup studio that incubates seed-stage medtech, biotech, and healthtech companies in preparation for follow-on investment from the main Santé Ventures funds. Together, these offerings reflect a unified platform where proprietary AI-driven investment technology and human-led company creation reinforce the firm's broader thesis of identifying innovative healthcare companies addressing unmet medical needs.

Differentiator

Problem solved

Functional benefit

Brands

  • Santé Capital: Publicly traded securities investment arm using the proprietary MindRank™ systematic quantitative strategy built on big data, machine learning, and natural language processing
  • Santé Accel

Products and services

  • Santé Ventures (Private Venture Capital) Private investment vehicle deploying capital into innovative early-stage healthcare companies with a focus in Biotech, Medtech, and Healthtech. Manages over $1 billion in capital across five venture funds and 60+ portfolio companies. Targeted at founders and institutional limited partners.
  • Santé Capital (Systematic Liquid Hedge Fund) Public securities strategy utilizing a systematic quantitative investment approach built on the proprietary MindRank™ software to generate risk-adjusted returns in mispriced publicly traded securities. Distributed to institutional LPs, family offices, and accredited investors via the firm's in-house capital formation team.
  • Santé Accel (Startup Studio) Santé start-up studio focused on creating and fostering seed-stage medtech, biotech, and healthtech opportunities through incubation, company formation, talent matching, and coaching, preparing companies for follow-on investment from Santé's main funds.
  • Santé Ventures Fund V Fifth and largest venture fund of Santé Ventures, closed with $330 million in committed capital, focused on early-stage investments in biotechnology, medical technology, and digitally enabled healthcare companies addressing unmet medical needs.

Quantifiable outcome

  • $70 billion+ in combined acquisition value for three portfolio companies Louis Bock guided (SeaGen/Pfizer $43B, Horizon Therapeutics/Amgen $27B, Zogenix/UCB $2B)
  • +4 more outcomes

Companies that use Sante Ventures

Customer profile

Segments5 records

Ideal customer profiles4 records

Sante Ventures technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Sante Ventures partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Sante Ventures competitors and assessment

Company assessment

Direct peers

  • Longitude Capital: Healthcare-dedicated growth and venture firm investing in biotech, medtech, and healthtech; similar fund size, sector focus, and growth-stage orientation to Santé Ventures Funds III–V.
  • RA Capital Management: Healthcare-focused crossover fund that invests across public and private biotech and medtech; comparable to Santé's dual private venture + public systematic strategy and similar size/AUM profile.
  • Versant Ventures: Healthcare-focused venture firm investing across biotech, medtech, and healthtech with offices in the US, Canada, and Europe; comparable fund size, sector mix, and company-creation approach to Santé.
  • Atlas Venture: Early-stage biotech-focused venture firm that builds companies from inception in a model analogous to Santé Accel; comparable seed/Series A orientation, though with heavier biotech weighting and smaller fund sizes.
  • Bain Capital Life Sciences: Dedicated life sciences platform within Bain Capital investing across biotech, medtech, and pharma services; co-investor with Santé (e.g., Apreo Health) and a directly comparable scaled healthcare specialist.
  • OrbiMed: Healthcare-dedicated investment firm managing roughly $17B across private equity, growth equity, and public equity strategies spanning biotech, medtech, and diagnostics — directly comparable to Santé's combined Santé Ventures + Santé Capital platform.
  • Frazier Healthcare Partners: Dedicated healthcare venture and growth firm investing across biotech, medtech, and pharma services with multiple sequential funds — closest peer in fund size, sector mix, and growth-stage focus.
  • 5AM Ventures: Early-stage life sciences venture firm investing in biotech and medtech with multiple sequential funds; closely comparable in fund size, sector focus, and operational value-add model.

Broad incumbents

  • ARCH Venture Partners: Large, established healthcare and technology venture firm with multiple billion-dollar funds and broad biotech/medtech exposure; comparable thesis area but materially larger and more biotech-skewed than Santé.
  • New Enterprise Associates (NEA): Multi-stage venture firm with a dedicated healthcare practice investing across biotech, medtech, and healthtech; broader sector mandate than Santé but directly competitive for the same Series A/B healthcare rounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Sante Ventures social profiles

Digital presence

Sante Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sante Ventures leadership team

Management profile

Number of profiles

Profiles28 records

Sante Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sante Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sante Ventures M&A and investment

M&A and investment

M&A

Investments118 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sante Ventures

What does Sante Ventures do?

Santé Ventures is a healthcare and life sciences venture capital firm that invests in early-stage private companies across Biotech, Medtech, and Healthtech verticals, managing over $1 billion in capital across five venture funds and 60+ portfolio companies. Through its subsidiary Santé Capital, the firm also operates a systematic liquid hedge fund strategy using its proprietary MindRank™ AI/ML/NLP software to capture mispricing in publicly traded securities, and runs Santé Accel, a startup studio that incubates seed-stage opportunities.

Is Sante Ventures a public or private company?

Sante Ventures is a private company. It is classified as management employee owned and is currently operating.

When was Sante Ventures founded?

Sante Ventures was founded in 2006. It employs 101 to 250 people.

Where is Sante Ventures based?

Sante Ventures is headquartered in Austin, United States, in the North America region.

How does Sante Ventures make money?

Two revenue lines are on record. Venture Capital Fund Management is the primary driver. The others are santé Capital Systematic Hedge Fund.

Who are Sante Ventures's main competitors?

Direct peers on record are Longitude Capital, RA Capital Management, Versant Ventures, Atlas Venture, Bain Capital Life Sciences, OrbiMed, Frazier Healthcare Partners and 5AM Ventures. Broad incumbents are ARCH Venture Partners and New Enterprise Associates (NEA).

Does Sante Ventures have an API?

No public API is recorded for Sante Ventures.

What industry is Sante Ventures in?

Sante Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAK, Secondary Venture Funds (VC Secondaries), with a secondary code of FSANAAAL, Venture Debt Providers. Its NAICS code is 525990.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magRapidPulse Pockets $48 Million for Stroke Aspiration Tech DevelopmentRapidPulse closed a $48 million Series B round co-led by Medtronic, TechWald, and S3 Ventures. The financing will complete its TURBO study and expand clinical experience, with potential FDA approval if data permits.MorningstarJaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar ProgramJaguar LAA, Inc. acquired assets related to the Laminar program from Johnson & Johnson, focusing on left atrial appendage closure for non-valvular atrial fibrillation. The transaction brings key assets together with the development team in a newly formed independent company, with financial terms undisclosed. Jaguar intends to advance the program through development and regulatory review.Venture Capital Access OnlineRapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration TechnologyRapidPulse closed a $48 million Series B financing co-led by Medtronic, TechWald Next, and S3 Ventures. The funds will support its TURBO study and expansion of its pulsed aspiration technology. The company aims to seek FDA approval for its system.The Straits TimesNew platform for healthcare startup growthSanté Accel Singapore, a healthcare venture-building platform, was launched in Singapore during the Singapore Medical Device Venture Showcase to support medtech, biotech, and healthtech startups with funding, mentorship, and global networks. The initiative is a partnership between US-based Sante Ventures—which closed a US$330 million fifth funding round in February and manages US$1.1 billion across five funds—and Singapore's SG Growth Capital, with a goal to invest several million dollars and set up at least four startups in the Republic over three years. The Health Sciences Authority also announced a partnership with Fogarty Innovation to enhance regulatory capabilities for medtech ventures.MedCity NewsWindward Bio Secures $165M for Clinical Trials in Asthma, COPD & MoreWindward Bio raised $165 million in a crossover round led by OrbiMed to advance its TSLP-blocking antibody WIN378. The drug is in Phase 2/3 testing with Phase 3 expected to start in Q4, and a COPD trial is planned this quarter. The funding extends its cash runway to reach multiple clinical trial readouts within 12 months.The Pharma LetterSonire raises $18 million to advance oncology programSonire Therapeutics raised $18 million in Series A financing led by Santé Ventures to advance its non-invasive cancer therapy for pancreatic cancer. The funding will support ongoing clinical trials, regulatory progress in the USA, and broader commercialization plans.TechStartupsParasail raises $32M to build ‘AI Supercloud’ that deploys and scales AI agents in minutesParasail raised $32 million in Series A funding, bringing its total to $42 million, to build an AI Supercloud that aggregates GPU compute. The company processes over 500 billion tokens daily and reports 30% month-over-month revenue growth. It aims to let developers deploy AI endpoints in minutes without vendor lock-in.TechStartupsTop Startup and Tech Funding News – April 15 2025On April 15, 2026, multiple startups raised funding across AI, biotech, space, and climate sectors. Beeline Medicines led with a $300M Series A, while Terremoto Biosciences raised $108M Series C and Turion Space $75M+ Series B. The rounds reflect investor focus on AI infrastructure, agentic systems, and space-based intelligence.TechStartupsSnap lays off 1,000 employees, or 16% of workforce, as AI takes over 65% of coding workSnap Inc. announced layoffs of about 1,000 employees, roughly 16% of its full-time staff, and closure of over 300 open roles. The cuts follow AI generating more than 65% of new code, with the company targeting $500 million in annual expense reductions. Snap is set to report earnings on May 6.FierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentCalifornia-based medtech company E2 (Endovascular Engineering) has raised $80 million in a Series C funding round to commercialize its Hēlo Thrombectomy Platform for treating pulmonary embolism, which received FDA clearance late last year. The financing, co-led by Gilde Healthcare and Norwest with participation from Santé Ventures and 415 Capital, was oversubscribed and will support commercial expansion and continued R&D investments. The company enters an increasingly competitive space alongside major medtech players including Stryker and Boston Scientific, which have made significant acquisitions in mechanical thrombectomy.